The Study Collect Clinical Data From the Treatment of Liver Cancer With New Drugs After 2019 and Integrate Biochemical and Pathological Indicators to Analyze Prognostic Outcomes, Including Overall Survival, Progression-free Survival, and Complications.

Hepatocellular carcinoma (HCC) is one of the most significant cancers in our country. Since 2019, many first-line and second-line therapeutic agents for HCC have been introduced. This study aims to evaluate the treatment outcomes of HCC patients in our hospital from 2019 to 2024 who received therapies other than the traditional sorafenib (Nexavar). The included drugs are Pembrolizumab, Atezolizumab (Tecentriq), Nivolumab, Lenvatinib, and Regorafenib (Stivarga). The study will collect clinical data from treated-cases with these novel agents after 2019 and integrate biochemical and pathological indicators to analyze prognostic outcomes, including overall survival, progression-free survival, and complications.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Liver Cancer Atezolizumab Digestive System Diseases Digestive System Neoplasms Lenvatinib Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Site Pembrolizumab

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

National Taiwan University Hospital

Taipei, 100, Taiwan

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Hepatocellular carcinoma participants who received treatment at National Taiwan University Hospital between January 1, 2019, and June 30, 2026, and had used the following medications.

Pembrolizumab /keytruda
Atezolizumab / Tecentriq
Nivolumab
Lenvatinib
Stivarga

Exclusion criteria

None

Treatment and study plan

Primary outcomes

liver cancer response of evaluation according to RECIST and mRECIST criteria

Time frame: 3 years

Sponsors and collaborators

Lead sponsor

National Taiwan University Hospital

Other

Registry information

Official study title

The Theraprutic Effect of New Drugs for Hepatocellular Carcinoma

Important dates

Study start: 2023
Primary completion: 2026
Study completion: 2026
First posted: Nov 18, 2025
Registry last updated: Nov 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting